Spyre Therapeutics (SYRE) Operating Expenses (2015 - 2026)

Spyre Therapeutics has reported Operating Expenses for 12 years, with the latest figure at $45.6 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 14.8% year-over-year to $45.6 million; the trailing twelve-month figure through Mar 2026 stood at $201.6 million (down 5.94% YoY), and the FY2025 full-year result was $209.6 million, changed 0.48% from the prior year.
• Operating Expenses for Q1 2026 stood at $45.6 million, down from $57.2 million in the prior quarter.
• The five-year high for Operating Expenses was $159.9 million in Q2 2023, with the low at $18.3 million in Q3 2023.
• Historically, Operating Expenses has averaged $46.7 million across 5 years, with a median of $45.6 million in 2026.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 593.92% — and 2024, when it plunged 72.4%.
• Spyre Therapeutics' Operating Expenses stood at $19.3 million in 2022, then surged by 137.53% to $45.9 million in 2023, then soared by 33.41% to $61.3 million in 2024, then retreated by 6.66% to $57.2 million in 2025, then declined by 20.17% to $45.6 million in 2026.
• The last three Operating Expenses figures came in at $45.6 million (Q1 2026), $57.2 million (Q4 2025), and $56.9 million (Q3 2025), per Business Quant data.